fillwise.fillwise.

Look up one drug

Ontario coverage, price, criteria word for word, Health Canada status and shortages for one product

Medication plan: estimated costs for a whole medication list

Buserelin acetate

All products: general benefit

Suprefact Depot 2 Months · DIN 02228955 · 6.3 mg · Implant Kit

General benefitDormant since November 1, 2025 · checked November 17, 2026 · What does dormant mean?
StatusGeneral benefit
Write on scriptno code needed
Patient paysNot calculated: no patient details entered. Add age and coverage above to see what this patient would pay.
Private plan not entered. Private-plan coverage, and how it coordinates with public programs, is not determined here; the Ontario public-program lines on this page remain conditional on the entered details and the program rules.
No interchangeable product listed in the Ontario extract
Suprefact Depot 2 Months · DIN 02228955 Manufacturer: Cheplapharm Arzneimittel GmbH; listing date 1997-04-10 Health Canada: Dormant since 2025-11-01 · brand SUPREFACT DEPOT 2 MONTHS · ATC L02AE01 BUSERELIN · form Implant · route Subcutaneous · ingredients BUSERELIN (BUSERELIN ACETATE) 6.3 MG · company Cheplapharm arzneimittel gmbh · schedule Prescription
Re-check Health Canada status and shortages (live) · Health Canada product record

Suprefact Depot 2 Months: Formulary list price $929.23 per unit (the source does not state the unit; exact figure $929.2348). What the ministry pays, not the patient.

Ministry pays: $929.2348 per source unit.

Source explanation: The formulary price is what ODB pays; the cash price at the counter is set by the pharmacy.

Formulary data: Ontario extract of September 22, 2026 · Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · Health Canada DPD page · Verify on the e-Formulary ↗ (DIN 02228955)

Source record
DIN 02228955: Suprefact Depot 2 Months Raw flags: sec3=Y Item: 100000111; group id 147; item number 0247; lccId None; manufacturer id CHE Source form: Implant Kit; strength: 6.3mg Recorded listing: General benefit Source prices (unrounded): $929.2348; ministry $929.2348 Source: ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=September 22, 2026 DIN=02228955 Health Canada DPD extract of October 5, 2026 (Open Government Licence – Canada) · https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=43499
Shortage status: not checked (no credentials)
Health Canada lists this DIN as Dormant since November 1, 2025 — choose a marketed DIN from the same-category list.

Other products in the same Health Canada class (L02A, L02AE): coverage varies; not interchangeable

  • Goserelin (Zoladex): general benefit
  • Leuprolide (Lupron Depot PDS): general benefit
  • Triptorelin (Trelstar (1 Month)): general benefit
  • Megestrol (Megace): general benefit, not a benefit
Other drugs in the same formulary class (10:00 ANTINEOPLASTIC AGENTS) and how they are covered

Matched class: 10:00 ANTINEOPLASTIC AGENTS

Drug-class inventory only. Lists recorded Ontario formulary products, not every Canadian medication; does not recommend treatment. Covered without a code on the Ontario formulary: ABIRATERONE ACETATE, ALTRETAMINE, ANASTROZOLE, BUSULFAN, CAPECITABINE, CHLORAMBUCIL, CYPROTERONE ACETATE, DAUNORUBICIN, DEGARELIX ACETATE, ETOPOSIDE, EXEMESTANE, FLUOROURACIL & SALICYLIC ACID, FULVESTRANT, GOSERELIN ACETATE, HYDROXYUREA, IMATINIB MESYLATE, LETROZOLE, LEUPROLIDE ACETATE, MELPHALAN, MERCAPTOPURINE, MITOTANE, PROCARBAZINE HCL, TEMOZOLOMIDE, THIOGUANINE, TRIPTORELIN PAMOATE Some products covered without a code (check the product listing): BICALUTAMIDE, CYCLOPHOSPHAMIDE, FLUTAMIDE, LOMUSTINE (CCNU), MEGESTROL ACETATE, METHOTREXATE, TAMOXIFEN CITRATE, VINCRISTINE SULFATE 10:00 ANTINEOPLASTIC AGENTS

GOSERELIN ACETATE

· 2 products · General benefit · strengths: 3.6mg, 10.8mg · Depot Inj

LEUPROLIDE ACETATE

· 11 products · General benefit · strengths: 3.75mg, 7.5mg, 11.25mg, 22.5mg, 30mg, 3.75mg/Vial, 22.5mg/Vial, 45mg · Inj-Kit, Pd for Inj - Vial Pk, Pd Susp Inj-Pref Syr Kit

TRIPTORELIN PAMOATE

· 5 products · General benefit · strengths: 3.75mg/Vial, 11.25mg/Vial, 22.5mg/Vial · Inj Pd with Sterile Water-Vial Pk, Inj Pd-Vial Pk, SR Inj Pd with Sterile Water-Vial Pk

MEGESTROL ACETATE

· 4 products · Listed, not a benefit (2), General benefit (2) · strengths: 40mg, 160mg · Tab

ABIRATERONE ACETATE

· 18 products · General benefit · strengths: 250mg, 500mg · Tab

ALTRETAMINE

· 1 products · General benefit · strengths: 50mg · Cap

ANASTROZOLE

· 18 products · General benefit · strengths: 1mg · Tab

BICALUTAMIDE

· 9 products · Listed, not a benefit (1), General benefit (8) · strengths: 50mg · Tab

BUSULFAN

· 1 products · General benefit · strengths: 2mg · Tab

CAPECITABINE

· 15 products · General benefit · strengths: 150mg, 500mg · Tab

CHLORAMBUCIL

· 1 products · General benefit · strengths: 2mg · Tab

CYCLOPHOSPHAMIDE

· 3 products · General benefit (2), Listed, not a benefit (1) · strengths: 25mg, 50mg · Tab Source: formulary-ed43-front-matter.txt Part V; ODB odb-formulary-ed43-extract-2026-09-22.xml extract_date=2026-09-22; class 10:00 and 34 more
Full class listing Related classes: Same formulary class, not same indication: class membership alone does not establish equivalent uses.
What the Health Canada label says it is for
INDICATIONS AND CLINICAL USE SUPREFACT® (buserelin acetate) is indicated for: Subcutaneous injection:  The palliative treatment (initial and maintenance treatment) of patients with hormone- dependent advanced carcinoma of the prostate gland (Stage D). Nasal solution:  The palliative treatment (maintenance treatment) of patients with hormone-dependent advanced carcinoma of the prostate gland (Stage D).  The treatment of endometriosis in patients who do not require surgery as primary therapy. The duration of treatment is usually six months and should not exceed nine months. SUPREFACT injection should be administered under the supervision of a health care professional. Geriatrics: No data is available. Page 3 of 57 Pediatrics (< 18 years of age): Experience with SUPREFACT for the management of endometriosis has been limited to women 18 years of age and older. https://pdf.hres.ca/dpd_pm/00056627.PDF PM date: June 2, 2020 Source product: SUPREFACT; DIN 02225166; fetched 2026-09-10 Product monograph posted by Health Canada; excerpt for lookup only.
Health Canada: dormant products
Health Canada defines dormant products as: “products that were previously marketed in Canada but for which the manufacturer has suspended sale for period of at least 12 months.” (canada.ca, September 10, 2026 ↗)